Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.

Department of Psychology, University of Washington, Seattle 98195-1525, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 05/2008; 69(6):999-1005. DOI: 10.4088/JCP.v69n0617
Source: PubMed

ABSTRACT This double-blind study examined whether olanzapine augments the efficacy of dialectical behavior therapy (DBT) in reducing anger and hostility in borderline personality disorder patients.
Twenty-four women with borderline personality disorder (DSM-IV criteria) and high levels of irritability and anger received 6 months of DBT. Subjects were randomly assigned to receive either low-dose olanzapine or placebo and were assessed with standardized measures in a double-blind manner. The study was conducted from September 2000 to December 2002.
Intent-to-treat analyses indicated that both treatment conditions resulted in significant improvement in irritability, aggression, depression, and self-inflicted injury (p < .01 for each). Irritability and aggression scores tended (p < .10) to decrease more quickly for the olanzapine group than for the placebo group. Self-inflicted injury tended (p < .10) to decrease more for the placebo group than for the olanzapine group.
Olanzapine may promote more rapid reduction of irritability and aggression than placebo for highly irritable women with borderline personality disorder. Effect sizes were moderate to large, with the small sample size likely limiting the ability to detect significant results. Overall, there were large and consistent reductions in irritability, aggression, depression, and self-injury for both groups of subjects receiving DBT.


Available from: Marsha M Linehan, Feb 25, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The current study examined the relationship between facets of mindfulness, partner-specific anger management, and female perpetrated dating violence. In addition, we examined whether anger management mediated the relation between mindfulness and psychological and physical aggression perpetration. Method: Female undergraduate students (n = 481) completed self-report measures of mindfulness, partner-specific anger management, and dating violence perpetration. Results: The mindfulness facets of nonreactivity, act with awareness, and nonjudging, as well as anger management, were associated with dating violence perpetration. After controlling for dating violence victimization, structural equation modeling (SEM) demonstrated that anger management fully mediated the relation between nonreactivity and act with awareness and psychological and physical aggression perpetration. Moreover, specific anger management components (escalating strategies and negative attributions) were largely responsible for the mediation findings. Conclusions: This is one of the first studies to demonstrate a relation between mindfulness and aggression perpetration, and the first to examine theoretically proposed mechanisms responsible for this relationship. Dating violence prevention programs may benefit from including mindfulness-based interventions to improve anger management and reduce aggressive behavior. (PsycINFO Database Record (c) 2014 APA, all rights reserved)
    Psychology of Violence 01/2014; 4(1):51. DOI:10.1037/a0033658 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug treatment of patients with borderline personality disorder (BPD) is common but mostly not supported by evidence from high-quality research. This review summarises the current evidence up to August 2014 and also aims to identify research trends in terms of ongoing randomised controlled trials (RCTs) as well as research gaps. There is some evidence for beneficial effects by second-generation antipsychotics, mood stabilisers and omega-3 fatty acids, while the overall evidence base is still unsatisfying. The dominating role SSRI antidepressants usually play within the medical treatment of BPD patients is neither reflected nor supported by corresponding evidence. Any drug treatment of BPD patients should be planned and regularly evaluated against this background of evidence. Research trends indicate increasing attention to alternative treatments such as dietary supplementation by omega-3 fatty acids or oxytocin.
    Current Psychiatry Reports 01/2015; 17(1):534. DOI:10.1007/s11920-014-0534-0 · 3.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A number of studies have demonstrated the anti-aggressive properties of clozapine in schizophrenia and its positive effect in borderline personality disorder. There is no published literature on the treatment of antisocial personality disorder (ASPD) with clozapine. We present a case series of 7 patients with primary ASPD and high psychopathic traits treated with clozapine, having a significant history of serious violence and currently detained in a UK based high-security hospital. A retrospective review of case notes was carried out to formulate Clinical Global Impression (CGI) scores and record incidents of violence and aggression. Effect on specific symptom domains (cognitive-perceptual, impulsive-behavioural dyscontrol, affective dysregulation) was also noted. Metabolic parameters and serum clozapine levels were also sampled. All 7 patients showed significant improvement on clozapine. It was shown to benefit all symptom domains, especially impulsive behavioral dyscontrol and anger. The number of violent incidents committed by 6 of the 7 patients reduced significantly, and all patients' risk of violence reduced. Clozapine serum levels for 6 of the 7 patients were in the range 150-350 ng/mL. Clozapine is of benefit in reducing the clinical severity of ASPD. It improved all symptom domains, especially impulsive-behavioral dyscontrol and anger, and reduced levels of aggression and violence, especially at lower doses (serum levels <350 ng/m). To our knowledge, this is the first account of clozapine treatment in patients with ASPD and high psychopathy.
    CNS spectrums 04/2014; 19(5):1-12. DOI:10.1017/S1092852914000157 · 1.30 Impact Factor